Cleared Traditional

K220608 - Accu-Chek FastClix Blood Lancing System (FDA 510(k) Clearance)

Apr 2022
Decision
58d
Days
Class 2
Risk

K220608 is an FDA 510(k) clearance for the Accu-Chek FastClix Blood Lancing System. This device is classified as a Multiple Use Blood Lancet For Single Patient Use Only (Class II - Special Controls, product code QRL).

Submitted by Roche Diabetes Care, Inc. (Indianapolis, US). The FDA issued a Cleared decision on April 29, 2022, 58 days after receiving the submission on March 2, 2022.

This device falls under the General & Plastic Surgery FDA review panel. Regulated under 21 CFR 878.4850. A Multiple Use Capable Blood Lancet Intended For Use On A Single Patient That Is Comprised Of A Single Use Blade Attached To A Solid, Reusable Base That Is Used To Puncture The Skin To Obtain A Drop Of Blood For Diagnostic Purposes..

Submission Details

510(k) Number K220608 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 02, 2022
Decision Date April 29, 2022
Days to Decision 58 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary Summary PDF

Device Classification

Product Code QRL - Multiple Use Blood Lancet For Single Patient Use Only
Device Class Class II - Special Controls
CFR Regulation 21 CFR 878.4850
Definition A Multiple Use Capable Blood Lancet Intended For Use On A Single Patient That Is Comprised Of A Single Use Blade Attached To A Solid, Reusable Base That Is Used To Puncture The Skin To Obtain A Drop Of Blood For Diagnostic Purposes.